Biodistribution of ¹⁷⁷Lu-OI-3 variants in mice bearing OHS xenografts.

<p>Comparison of biodistribution of ¹⁷⁷Lu-labeled murine OI-3, chimeric IgG1 OI-3 (CHOI-3.1) and chimeric IgG3 OI-3 (CHOI-3.3) in nude mice with OHS osteosarcoma xenografts. The data are presented as percentage of injected dose per gram tissue at 24 (A) and 48 hours (B) after injection, with error bars corresponding to the standard error of the mean. Three to six mice were used in each group, giving four to eight tumors per time point.</p

CD146 expression in human osteosarcoma cell lines.

<p>A representative flow cytometry histogram that compare the binding of murine anti-CD146 OI-3 antibody to three different human osteosarcoma cell lines: OHS (A), Saos-2 (B) and KPDX (C). Control samples are unstained cells and cells stained only with the FITC-conjugated secondary antibody (ab). In addition, the binding of murine anti-CD37 antibody HH1 was examined for OHS (A) and Saos-2 (B) cells. The samples were analyzed on a BD FacsCalibur.</p

Biodistribution of ¹⁷⁷Lu-CHOI-3.1 in mice bearing OHS xenografts.

<p>Biodistribution of ¹⁷⁷Lu-labeled chimeric OI-3 IgG1 isotype antibody (CHOI-3.1) in tissues of interest in OHS xenograft-carrying nude mice. At each time point from three to six animals were used, with number of tumors ranging from five to twelve per group. Straight lines have been drawn to connect the data points. The error bars correspond to the standard error of the mean.</p

Biodistribution of ¹²⁵I-labeled antibodies in mice bearing OHS xenografts.

<p>Tumor to normal tissue ratios 24 hours after injection of ¹²⁵I-labeled antibodies in female nude mice bearing OHS tumor xenografts. Four to five animals were used for each radioimmunoconjugate, which gave from four to seven tumors per group. Error bars correspond to standard error of the mean.</p

Comparison of the binding ability of chimeric antibodies targeting different antigens on OHS cells.

<p>A representative flow cytometry histogram which shows binding of the chimeric versions of OI-3 to OHS cells, compared with samples incubated with cetuximab, trastuzumab and rituximab. Control samples are unstained cells and cells stained only with the FITC-conjugated secondary antibody (ab). The samples were run on a Guava EasyCyte HT. Take note that the samples with chimeric antibodies were run on a different platform, with different settings and secondary antibody, and the fluorescence intensity levels are therefore not directly comparable to runs with murine OI-3 in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0165382#pone.0165382.g001" target="_blank">Fig 1</a>.</p

Absorbed radiation doses to normal tissues and tumors.

<p>Estimated absorbed radiation dose (Gy) to normal tissues and tumors for nude mice with OHS osteosarcoma xenografts after intravenous injection of ¹⁷⁷Lu-labeled chimeric OI-3 IgG1 isotype antibody (CHOI-3.1). The data were normalized to an injected activity of 1 MBq per mouse. Error bars correspond to standard deviation.</p